Regulatory Framework · 2.4 Substance Market Regulations

Partial compliance.

Mexico has a concrete legal and regulatory basis for the quality and labeling of products subject to sanitary control. The General Health Law establishes the national basis for authorization, surveillance, labeling, importation, exportation, and sanitary control of products, services, and health supplies. This framework covers medicines, substances subject to sanitary control, and therapeutic products, but it functions mainly as a structural foundation.

The Health Supplies Regulation strengthens this dimension because it regulates medicines, herbal remedies, narcotics, and psychotropics within therapeutic products. Its link to the indicator is more direct than a general product rule because it addresses sanitary registration, manufacturing, packaging, labeling, and sanitary control of health supplies. However, it does not by itself demonstrate sufficient inspections, applied sanctions, batch control, concentration verification, or effective market labeling.

The most cannabis-specific source is the 2021 Regulation on the production, research, and medical use of cannabis and its pharmacological derivatives. This regulation establishes formal standards for medical cannabis: raw materials, derivatives, medicines, manufacturing, commercialization, packaging, labeling, traceability, and quality control within the medical circuit. This supports recognition of real regulatory progress, but limited to the medical and pharmacological field.

NOM-051 provides a mandatory labeling standard for prepackaged foods and non-alcoholic beverages, including warnings and consumer information. Its role in this indicator is contextual and indirect: it shows Mexico’s regulatory capacity for preventive labeling, but it does not regulate potency, concentration, purity, contaminants, or specific warnings for cannabis, narcotics, psychotropics, or other regulated psychoactive substances.

The indicator does not reach full compliance because the evidence does not confirm a specific, operational, and evaluated system for quality and labeling of regulated psychoactive products. No consolidated public data were located on potency, concentration, contaminants, batch information, specific health warnings, effective traceability, active cannabis sanitary registrations, inspections, sanctions, or compliance outcomes. Mexico City, Puebla, Oaxaca, Chiapas, and the complementary states remain territorial probatory gaps.

Consequently, Mexico demonstrates relevant formal regulation for quality and labeling, especially for health supplies and medical cannabis, but not sufficient evidence of a specific, verifiable, and operationally applied system for cannabis products or regulated psychoactive substances.